Huagai Capital

Huagai Capital is a private equity investment firm based in Beijing, China, founded in 2012. The firm specializes in investing in start-up and growth-stage companies within the healthcare, technology, media, and telecommunications (TMT), and cultural sectors. By focusing on these areas, Huagai Capital aims to support innovative businesses that have the potential for significant impact and growth.

Xiaolin Xu

Chairman and Co-Founder

Zeng Zhiqiang

Managing Partner

Wang Shaokun

Vice President

Past deals in Beijing

Beijing Sudo Technology

Series A in 2021
Beijing Sudo Technology provides privacy protection technical services from the perspective of systematic comprehensive engineering.

Datong

Private Equity Round in 2021
Datong Insurance is a professional third-party financial insurance service organization. Datong’s subsidiaries include Datong Insurance Sales Service Co., Ltd., Beijing Datong Insurance Brokers Co., Ltd., among which Datong Insurance Sales Service Co., Ltd. is approved by the China Insurance Regulatory Commission. The first national insurance professional sales and service organization approved to be established. At present, the Datong service network has covered more than 20 provinces and municipalities across the country.

EdiGene

Series B in 2021
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Synaptic Medical

Series G in 2021
Synaptic Medical Inc. is a medical device company that develops and commercializes products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Founded in 2005, the company operates from its headquarters in St. Paul, Minnesota, and has an additional office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology products, including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation technologies. The company's mission is to create innovative, cost-effective, and clinically advanced solutions that enhance treatment options for physicians and their patients.

EdiGene

Series B in 2020
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

AccuMedical

Series B in 2020
AccuMedical is a full-line product company in the field of neurological intervention, headquartered in Beijing with an R&D center located in California. It develops and produces medical device products for the treatment of aneurysms, preventing, and treating bleeding diseases caused by the rupture of vascular aneurysms.

Shukun

Series B in 2020
Shukun Technology is a Chinese healthcare company, established in 2017 and based in Beijing, that focuses on developing diagnostic systems utilizing machine learning and artificial intelligence. The company specializes in assisting medical professionals with the diagnosis of cardiovascular diseases and tumors by employing deep learning algorithms to analyze medical images. This technology enables the automatic identification of lesions and the generation of diagnostic reports, thereby enhancing the efficiency of the diagnostic process for doctors and improving the quality of care provided in primary hospitals.

Galaxis Automotion

Series D in 2020
Galaxis technology group, founded in 2014, is a high-tech enterprise focusing on providing integrated logistics automation and robotics solutions and one-stop service. It brings together first-class technical experts and teams from home and abroad. With years of experience in logistics and technical accumulation, has more than hundreds of software copyright, and the national patent, formed the consulting including logistics system planning, software development, system integration, operation guidance, and multi-layer shuttle, high speed lift, AGV, sorting system such as the core research and development of high-end equipment manufacturing as a whole solution, the construction of logistics system can provide customers with one-stop service. High standards, refined product and service quality have kept the company in a leading position in the industry.The application cases are widely applied in more than 10 industries, such as medicine, e-commerce, clothing, books, rail,transit, automobile, etc., and more than 150 large and medium-sized modern logistics centers and production three-dimensional warehouses have been constructed, with the total investment of the project exceeding 20 billion rmb. Headquartered in Jiaxing, the group has technology r&d centers in Germany and Austria, subsidiaries or factories in eight cities of Shanghai, Beijing, Guangzhou, Wuhan, Jiaxing, Wuxi, Chengdu and Kunming. Their vision is to become the world's leading supplier of logistics robots and high-end equipment, technical service providers and system integrators. Focus on customers, continuous innovation, let the world do not hard logistics!

Shukun

Series B in 2019
Shukun Technology is a Chinese healthcare company, established in 2017 and based in Beijing, that focuses on developing diagnostic systems utilizing machine learning and artificial intelligence. The company specializes in assisting medical professionals with the diagnosis of cardiovascular diseases and tumors by employing deep learning algorithms to analyze medical images. This technology enables the automatic identification of lesions and the generation of diagnostic reports, thereby enhancing the efficiency of the diagnostic process for doctors and improving the quality of care provided in primary hospitals.

EdiGene

Series A in 2018
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Shukun

Series A in 2018
Shukun Technology is a Chinese healthcare company, established in 2017 and based in Beijing, that focuses on developing diagnostic systems utilizing machine learning and artificial intelligence. The company specializes in assisting medical professionals with the diagnosis of cardiovascular diseases and tumors by employing deep learning algorithms to analyze medical images. This technology enables the automatic identification of lesions and the generation of diagnostic reports, thereby enhancing the efficiency of the diagnostic process for doctors and improving the quality of care provided in primary hospitals.

Rebbeca Med

Series A in 2018
Rebecca is committed to the application of precision-controlled MEMS radio frequency technology in clinical disease control and rehabilitation. Its core technology comes from the core team's many years of experience and achievements in research and development and productization at the University of California, Fortune 500 medical equipment, and electronic equipment companies. The company cooperated with domestic university research institutes and many top three hospitals in Beijing, Shanghai, and Hangzhou to independently develop micro-radio frequency technology that surpassed similar products in Europe and America. It focuses on delivering innovative medical solutions to the hands of professional caregivers. Rebecca's team possesses technical expertise in micro-devices, RF, and device integration through years of field practice in micro-electronics and clinical innovation.

Rogrand

Series C in 2017
Beijing Rogrand E-Commerce Co., Ltd. is a leading pharmaceutical entire integration of industry chain service platform in China leading the innovation of new pharmaceutical business model. Since its inception in 2012, the company has always been driven by the goal of forging a circulation platform for the whole industry consisting of pharmaceutical industry, pharmaceutical business, pharmacy, clinic and medical institution.

CooTek

Series D in 2017
CooTek is a global mobile internet company founded in 2008 and headquartered in Shanghai, with additional offices in locations such as Silicon Valley and Beijing. The company specializes in developing innovative mobile applications and artificial intelligence technology, aiming to enhance user expression and content engagement. Its flagship product, TouchPal Keyboard, offers a superior input experience for both Android and iPhone users. CooTek's portfolio includes a variety of content-rich applications across multiple categories, including online literature, mobile games, and scenario-based apps in areas such as fitness and healthcare. The company boasts a substantial user base, with its products achieving an average of 213.7 million monthly active users globally in 2018. CooTek is also committed to technology innovation, holding over 170 patents and operating a big data development center and AI lab in Silicon Valley. Additionally, the company actively contributes to academic discourse in the fields of big data and AI, with research presented at prestigious conferences.

Octinn

Series A in 2014
Octinn is a Beijing-based birthday management and reminder app, which provides birthday reminder, e-card delivery, cake and gift sales services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.